HUMANIGEN INC COM USD0.001 (KBIO)

1.38
0.02 1.43
OTC
Prev Close 1.40
Open 1.33
Day Low/High 1.30 / 1.40
52 Wk Low/High 1.12 / 4.75
Volume 15.40K
Exchange OTC
Shares Outstanding 14.98B
Market Cap 25.87M
Div & Yield N.A. (N.A)

Latest News

KaloBios Receives Orphan Drug Designation For Benznidazole In The Treatment Of Chagas Disease

KaloBios Receives Orphan Drug Designation For Benznidazole In The Treatment Of Chagas Disease

Designation provides seven years market exclusivity upon approval

KaloBios Upgrades Stock To OTCQB Market

KaloBios Now Current On SEC Periodic Filings

KaloBios Now Current On SEC Periodic Filings

Submits outstanding reports for 2016 first and second quarters

KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Investor Alert: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In KaloBios Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Investor Alert: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In KaloBios Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

Doug Kass shares his views on Potash, Radian and oil, and revisits his prediction about KaloBios.

Stocks Slip on 2016 Outlook of Middling Economic Growth

Stocks Slip on 2016 Outlook of Middling Economic Growth

As Wall Street prepares to close out 2015 much where it started, investors looked to the year ahead to determine direction on the second-last day of trading.

Energy Lags Wall Street as Crude Oil Spirals Lower

Energy Lags Wall Street as Crude Oil Spirals Lower

Stocks move slightly lower as another selloff in crude oil prices hits the energy sector.